Loading
Adding trastuzumab to chemotherapy for HER2-positive uterine serous carcinoma, an aggressive endometrial cancer, lengthened progression-free survival by about four months and later showed a survival benefit, making HER2 testing routine in this subtype.
Randomised phase 2 trial of 61 women with HER2-positive (immunohistochemistry 3+ or amplified) advanced or recurrent uterine serous carcinoma treated with carboplatin-paclitaxel with or without trastuzumab continued as maintenance.
Median progression-free survival was 12.6 versus 8.0 months (hazard ratio 0.44), with the largest gain in newly diagnosed stage III to IV disease (17.9 versus 9.3 months); an update showed improved overall survival in that group.
HER2 testing of every serous endometrial cancer and trastuzumab with first-line chemotherapy for HER2-positive advanced disease are now guideline recommendations; trastuzumab deruxtecan extends the option.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Trastuzumab, Journal of Clinical Oncology.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Journal of Clinical Oncology.
Shares Trastuzumab, Journal of Clinical Oncology.
Shares Trastuzumab, Journal of Clinical Oncology.
Shares Trastuzumab, Carboplatin.
Shares Trastuzumab, Carboplatin.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Trastuzumab.
Shares Trastuzumab, Journal of Clinical Oncology.